This Article Full Text Full Text (PDF) All Versions of this Article: 36/8/1801    most recent 01.STR.0000174189.81153.85v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Gorelick, P. B. Articles by Weisman, S. M. Search for Related Content PubMed PubMed Citation Articles by Gorelick, P. B. Articles by Weisman, S. M. Related Collections Primary prevention

(Stroke. 2005;36:1801.)
© 2005 American Heart Association, Inc.

Comments, Opinions, and Reviews

Risk of Hemorrhagic Stroke With Aspirin Use

An Update

From the University of Illinois at Chicago.

Correspondence to Steven M. Weisman, PhD, 67 Park Place East, Morristown, NJ 07960. E-mail weisman{at}innovativescience.net

Background— Low-dose aspirin is an important therapeutic option in the secondary prevention of myocardial infarction (MI) and ischemic stroke, especially in light of its unique cost-effectiveness and widespread availability. In addition, based on the results of a number of large studies, aspirin is also widely used in the primary prevention of MI. This review provides an update of the available data to offer greater clarity regarding the risks of aspirin with respect to hemorrhagic stroke, as well as insights regarding patient selection to minimize the risk of this complication.

Summary of Review— In the secondary prevention of cardiovascular, cerebrovascular, and ischemic events, the evidence supports that the benefits of aspirin treatment significantly outweigh the risk of a major hemorrhage. The evidence from primary prevention of MI studies, including that from the recent Women’s Health Study evaluation of aspirin use in healthy women, demonstrate that the increased risk for hemorrhagic stroke is small, is comparable to the secondary prevention studies, and fails to achieve statistical significance. A reasonable estimate of the risk of hemorrhagic stroke associated with the use of aspirin in primary prevention patients is 0.2 events per 1000 patient-years, which is comparable to estimates of the risk associated with the use of aspirin in secondary prevention patients.

Conclusions— When considering whether aspirin is appropriate, the absolute therapeutic cardiovascular benefits of aspirin must be balanced with the possible risks associated with its use, with the most serious being hemorrhagic stroke.

Key Words: aspirin • intracerebral hemorrhage • primary prevention • stroke, hemorrhagic

This article has been cited by other articles:

				P. B. Gorelick Cerebral Microbleeds: Evidence of Heightened Risk Associated With Aspirin Use Arch Neurol, June 1, 2009; 66(6): 691 - 693. [Full Text] [PDF]

				M. W. Vernooij, M. D. M. Haag, A. van der Lugt, A. Hofman, G. P. Krestin, B. H. Stricker, and M. M. B. Breteler Use of Antithrombotic Drugs and the Presence of Cerebral Microbleeds: The Rotterdam Scan Study Arch Neurol, June 1, 2009; 66(6): 714 - 720. [Abstract] [Full Text] [PDF]

				P. Elwood and G. Morgan Aspirin for all over 50 revisited Heart, November 1, 2008; 94(11): 1364 - 1365. [Full Text] [PDF]

				N.-K. Choi, B.-J. Park, S.-W. Jeong, K.-H. Yu, and B.-W. Yoon Nonaspirin Nonsteroidal Anti-inflammatory Drugs and Hemorrhagic Stroke Risk: The Acute Brain Bleeding Analysis Study Stroke, March 1, 2008; 39(3): 845 - 849. [Abstract] [Full Text] [PDF]

				N. A. Nickman, J. Biskupiak, F. Creekmore, H. Shah, and D. I . Brixner Antiplatelet medication management in patients hospitalized with ischemic stroke Am. J. Health Syst. Pharm., November 1, 2007; 64(21): 2250 - 2256. [Abstract] [Full Text] [PDF]

				S. Khella and M. B. Bleicher Stroke and Its Prevention in Chronic Kidney Disease Clin. J. Am. Soc. Nephrol., November 1, 2007; 2(6): 1343 - 1351. [Abstract] [Full Text] [PDF]

				C. L. Campbell, S. Smyth, G. Montalescot, and S. R. Steinhubl Aspirin Dose for the Prevention of Cardiovascular Disease: A Systematic Review JAMA, May 9, 2007; 297(18): 2018 - 2024. [Abstract] [Full Text] [PDF]

				P. B. Gorelick Combining Aspirin With Oral Anticoagulant Therapy: Is This a Safe and Effective Practice in Patients With Atrial Fibrillation? Stroke, May 1, 2007; 38(5): 1652 - 1654. [Full Text] [PDF]

				N. E. Mayo, L. Nadeau, S. S. Daskalopoulou, and R. Cote The evolution of stroke in Quebec: A 15-year perspective Neurology, April 3, 2007; 68(14): 1122 - 1127. [Abstract] [Full Text] [PDF]

				L. Navarro-Nunez, M. L. Lozano, J. Rivera, J. Corral, V. Roldan, R. Gonzalez-Conejero, J. A. Iniesta, J. Montaner, V. Vicente, and C. Martinez The association of the {beta}1-tubulin Q43P polymorphism with intracerebral hemorrhage in men Haematologica, April 1, 2007; 92(4): 513 - 518. [Abstract] [Full Text] [PDF]

				S. Tuhrim Aspirin-Use Before ICH: A Potentially Treatable Iatrogenic Coagulopathy? Stroke, January 1, 2006; 37(1): 4 - 5. [Full Text] [PDF]